1. Merck to buy Pandion for $1.9B for its immune modulators — Biden looking beyond Woodcock or Sharfstein for FDA commmisioner — Former AveXis execs launch gene therapy startup See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Telehealth Email To Offices. Who’s safer?

Discussion in 'Exact Sciences' started by anonymous, Apr 10, 2020 at 11:58 AM.

  1. anonymous

    anonymous Guest

    Dear Dr.,

    In light of the COVID-19 pandemic, we are facing the challenge of finding new ways to live and work. Thank you for all that you are doing as a healthcare provider during this unprecedented time.

    Many healthcare providers are now using telehealth to continue to care for patients. At Exact Sciences, we also see the benefits of telehealth and want to ensure that people are aware that telehealth can play a role in screening for colorectal cancer (CRC).

    Our website, cologuardtest.com, will not only include the existing resources for patients to advance the conversation about screening with their provider about Cologuard®, a CRC screening option that can be used at home, but will also include information about telehealth in general, and a link to one such third-party, independent telehealth provider from whom they may request Cologuard. The telehealth provider will review patient information, risk factors, and determine if Cologuard is appropriate. This online offering is intended to support, not replace, screening efforts by providing additional resources for patients to advance CRC screening at this unprecedented time.

    Cologuard is intended to screen adults 45 years of age or older, who are at average risk for colorectal cancer. It is not a replacement for colonoscopy in high-risk individuals. Cologuard is available by prescription only.

    Cologuard is not for high-risk individuals, including patients with a personal history of colorectal cancer and adenomas; have had a positive result from another colorectal cancer screening method within the last 6 months; have been diagnosed with a condition associated with high risk for colorectal cancer such as IBD, chronic ulcerative colitis, Crohn's disease; or have a family history of colorectal cancer, or certain hereditary syndromes.

    Because cancer does not stop for anything, Exact Sciences Laboratories remains fully operational in our efforts to help you ensure that none of your patients go unscreened for CRC.

    Thank you,

    Your partners at Exact Sciences